Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

Association of nuclear factor κB expression with a poor outcome in nasopharyngeal carcinoma

Authors: Y. Zhang, J. Y. Lang, L. Liu, J. Wang, G. Feng, Y. Jiang, Y. L. Deng, X. J. Wang, Y. H. Yang, T. Z. Dai, G. Xie, J. Pu, X. B. Du

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

The aim of this study was to determine the relationship between nuclear factor κB and the prognosis of patients with nasopharyngeal carcinoma. We used immunohistochemical studies to examine nuclear factor κB expression in 42 patients with nasopharyngeal carcinoma. The results showed that tumors positive for nuclear factor κB were associated with an increased relapse potential, poor disease-free survival, and reduced overall survival in nasopharyngeal carcinoma. Our study indicates that nuclear factor κB could be an independent molecular marker for predicting poor prognosis among patients with nasopharyngeal carcinoma. Understanding the biology of nuclear factor κB-mediated pathways may lead to the development of novel therapeutic strategies for nasopharyngeal carcinoma.
Literature
1.
Hoppe RT, Williams J, Warnke R, Goffinet DR, Bagshaw MA. Carcinoma of the nasopharynx -the significance of histology. Int J Radiat Oncol Biol Phys. 1978;4:199–205.PubMedCrossRef
2.
Cheng SH, Liu TW, Jian JJ, Tsai SY, Hao SP, Huang CH, Liu MC, Yu B, Huang AT. Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. Cancer J Sci Am. 1997;3:100–6.PubMed
3.
Farias TP, Dias FL, Kligerman RALJ, Sa GMD, Barbosa MM, Gonc FB Jr. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:794–9.PubMedCrossRef
4.
Heng DM, Wee J, Fong KW, Lian LG, Sethi VK, Chua ET. Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer. 1999;86:1912–20.PubMedCrossRef
5.
Teo P, Yu P, Lee WY, Leung SF, Kwan WH, Yu KH. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys. 1996;36:291–304.PubMed
6.
O’Sullivan B, Chong V, Gospodarowicz MK. Nasopharyngeal carcinoma. In: Gospodarowicz MK, Henson DE, Hutter RVP, et al., editors. Prognostic factors in cancer, 2nd edition. UICC TNM project and prognostic factors committee. New York: John Wiley and Sons; 2001.
7.
Lo YMD, Chan ATC, Chan LYS. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein–Barr virus DNA. Cancer Res. 2000;60:6878–81.PubMed
8.
Sen R, Baltimore D. Inducibility of kappa immunoglobulins enhancer-binding protein NF-kB by a posttranslational mechanism. Cell. 1986;47:921–9.PubMedCrossRef
9.
Karin M, Cao Y, Greten FR, Li Z. NF-kB in cancer: from innocent bystander to major culprit. Nature Rev Cancer. 2002;2:301–10.CrossRef
10.
Bours V, Bonizzi G, Bentires-Alj M, Bureau F, Piette J, Lekeux P, Merville M. NF-kB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology. 2000;153:27–38.PubMedCrossRef
11.
Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–71.PubMedCrossRef
12.
Baeuerle P, Henkel T. Function and activation of NF-kB in the immune system. Annu Rev Immunol. 1994;12:141–79.PubMedCrossRef
13.
14.
Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin JAS. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785–99.PubMed
15.
Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kB transcription factors. Oncogene. 1999;18:6910–24.PubMedCrossRef
16.
Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241–6.PubMedCrossRef
17.
Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci USA. 1998;95:13012–7.PubMedCrossRef
18.
Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH. Association of activated transcription factor nuclear factor -kB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006;24:748–54.PubMedCrossRef
19.
Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol. 2007;25:3930–5.PubMedCrossRef
20.
Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res. 2005;11:8398–402.PubMedCrossRef
21.
Chen G, Bhojani MS, Heaford AC, Chang DC, Laxman B, Thomas DG. Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci USA. 2005;102:12507–12.PubMedCrossRef
22.
Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 2003;63:8293–301.PubMed
23.
Wong JH, Lui VW, Umezawa K, Ho Y, Wong EY, Ng MH. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett. 2010;287:23–32.PubMedCrossRef
24.
Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 1995;9:2723–35.PubMedCrossRef
25.
Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405–55.PubMedCrossRef
26.
27.
Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L, Kagnoff M, Karin M. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–96.PubMedCrossRef
28.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich PE, Urieli SS, Galun E, Ben NY. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.PubMedCrossRef
29.
Smirnov AS, Ruzov AS, Budanov AV, Prokhortchouk AV, Ivanov AV, Prokhotchouk EB. High constitutive level of NF-kappaB is crucial for viability of adenocarcinoma cells. Cell Death Differ. 2001;8:621–30.PubMedCrossRef
30.
Lindholm PF, Bub J, Kaul S, Shidman VB, Kajdacsy-Balla A. The role of constitutive NF-kB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis. 2000;18:471–9.PubMedCrossRef
31.
Nakayama H, Ikebe T, Beppu M, Shirasuna K. High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer. 2001;92:3037–44.PubMedCrossRef
32.
Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factorkappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res. 2000;6:2573–81.PubMed
33.
Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler I. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001;20(31):4188–97.PubMedCrossRef
34.
Lesage D, Metelev V, Borisova O, Dolinnaya N, Oretskaya T, Baran-Marszak F, Taillandier E, Raphael M, Fagard R. Specific covalent binding of a NF-kappaB decoy hairpin oligonucleotide targeted to the p50 subunit and induction of apoptosis. FEBS Lett. 2003;547:115–8.PubMedCrossRef
35.
Yamagishi N, Miyakoshi J, Takebe H. Enhanced radiosensitivity by inhibition of nuclear factor kappa B activation in human malignant glioma cells. Int J Radiat Biol. 1997;72:157–62.PubMedCrossRef
36.
Wang CY, Mayo MW, Baldwin AS Jr. TNF-a and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science. 1996;274:784–7.PubMedCrossRef
37.
Didelot C, Barberi-Heyob M, Bianchi A, Becuwe P, Mirjolet JF, Dauca M, Merlin JL. Constitutive NF-kB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines. Int J Radiat Oncol Biol Phys. 2001;51:1354–60.PubMedCrossRef
38.
Kato T, Duffey DC, Ondrey FG, Dong G, Chen Z, Cook JA, Mitchell JB, Van Waes C. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kB. Head Neck. 2000;22:748–59.PubMedCrossRef
39.
Kim KR, Yoshizaki T, Miyamori H, Hasegawa K, Horikawa T, Furukawa M, Harada S, Seiki M, Sato H. Transformation of Madin–Darby canine kidney (MDCK) epithelial cells by Epstein–Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene. 2000;19(14):1764–71.PubMedCrossRef
40.
Yin L, Liao W, Deng X, Tang M, Gu H, Li X, Yi W, Cao Y. LMP1 activates NF-kappa B via degradation of I kappa B alpha in nasopharyngeal carcinoma cells. Chin Med J. 2001;114(7):718–22.PubMed
41.
Lu JH, Tang YL, Yu HB, Zhou JH, Fu CY, Zeng X, Yu ZY, Yin HL, Wu MH, Zhang JY, Li XL, Li GY. Epstein-Barr virus facilitates the malignant potential of immortalized epithelial cells: from latent genome to viral production and maintenance. Lab Invest. 2010;90:196–209.PubMedCrossRef
42.
Liu H, Zheng H, Duan Z, Hu D, Li M, Liu S, Li Z, Deng X, Wang Z, Tang M, Shi Y, Yi W, Cao Y. LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells. Mol Cancer. 2009;8:92.PubMedCrossRef
43.
Li HM, Man C, Jin Y, Deng W, Yip YL, Feng HC, Cheung YC, Lo KW, Meltzer PS, Wu ZG, Kwong YL, Yuen AP, Tsao SW. Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. Int J Cancer. 2006;119:1567–76.PubMedCrossRef
Metadata
Title
Association of nuclear factor κB expression with a poor outcome in nasopharyngeal carcinoma
Authors
Y. Zhang
J. Y. Lang
L. Liu
J. Wang
G. Feng
Y. Jiang
Y. L. Deng
X. J. Wang
Y. H. Yang
T. Z. Dai
G. Xie
J. Pu
X. B. Du
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9571-7

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue

Original Paper

Disconnection of chamber and catheter as a complication of central venous catheter type port-a-cath

Original Paper

Altered expression of selenium-binding protein 1 in gastric carcinoma and precursor lesions

Original Paper

Inhibition of proliferation and gene expression regulation by (-)-epigallocatechin-3-gallate in human synovial sarcoma cells

Original Paper

Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection

Original paper

Epstein–Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy

Original paper

Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits